Skip to search formSkip to main contentSkip to account menu

sofosbuvir

Known as: Sofosbuvir [Chemical/Ingredient], L-Alanine, N-[[P(S),2'R]-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, 1-methylethyl Ester, 2-((5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)phenoxyphosphorylamino)propionic acid isopropyl ester 
An orally available nucleotide prodrug and a hepatitis C virus (HCV) NS5B polymerase inhibitor with potential HCV inhibiting activity. Upon oral… 
National Institutes of Health

Related topics

Related topics

20 relations

Broader (1)

Antiviral Agents

Narrower (5)

GS-7977HarvoniPSI 7977Sovaldi
Hepatitis CIn BloodNucleoside Analogsagonists

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus‐infected patients with decompensated liver disease
Approximately three million individuals in the United States are chronically infected with hepatitis C virus (HCV). Chronic HCV… 
2017
2017
Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES
Directly acting antiviral agents (DAA) have been associated with hepatic decompensation, especially in patients with pre… 
2017
2017
Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: Data from the Veterans administration
Data addressing real world effectiveness of direct acting antiviral agents in hepatitis C infected patients are now emerging… 
Highly Cited
2016
Highly Cited
2016
Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis
Combination antiviral therapy involving sofosbuvir (SOF) and simeprevir (SIM) is a treatment option in patients with genotype 1… 
Highly Cited
2016
Highly Cited
2016
L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions.
BACKGROUND Sofosbuvir (SOF) exhibits a high barrier to resistance, with no S282T NS5B substitution or phenotypic resistance… 
Highly Cited
2016
Highly Cited
2016
Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir‐containing regimen
Failure to achieve sustained virological response (SVR) with hepatitis C virus (HCV) direct‐acting antiviral‐based regimens is… 
Highly Cited
2015
Highly Cited
2015
Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients
Recurrent hepatitis C virus (HCV) infection occurs universally in the allograft in the absence of effective antiviral therapy… 
Review
2015
Review
2015
HCV targeting of patients with cirrhosis.
2014
2014
The beginning of the end: what is the future of interferon therapy for chronic hepatitis C?
2013
2013
HCV treatment--no more room for interferonologists?
The landscape of therapy for hepatitis C virus (HCV) infection is changing rapidly. Until recently, the standard of care for HCV… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)